Adaptimmune Therapeutics Plc

... ...
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 1.99%132.300.0%$3021.44m
BNGOBioNano Genomics, Inc. 24.32%8.640.0%$1462.88m
GILDGilead Sciences, Inc. 1.35%63.251.0%$660.24m
AMGNAmgen, Inc. 1.36%244.951.3%$593.70m
ALXNAlexion Pharmaceuticals, Inc. 0.21%156.982.0%$543.81m
CRSPCRISPR Therapeutics AG -2.17%205.480.6%$528.15m
NVAXNovavax, Inc. -0.28%129.6292.9%$493.87m
REGNRegeneron Pharmaceuticals, Inc. -0.53%515.172.7%$478.84m
ILMNIllumina, Inc. 2.15%379.033.5%$366.29m
BIIBBiogen, Inc. -0.79%278.091.7%$361.06m
VRTXVertex Pharmaceuticals, Inc. 0.06%226.251.9%$344.63m
BNTXBioNTech SE -4.58%101.000.0%$322.68m
SRPTSarepta Therapeutics, Inc. 1.31%91.0813.8%$287.33m
OCGNOcugen, Inc. 5.02%2.290.0%$283.75m
EDITEditas Medicine, Inc. 6.11%80.567.9%$260.09m

Company Profile

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.